A new era of psychedelic medicine
Novamind is building the infrastructure required for a regulated psychedelics industry
Why psychedelics?
“Psychedelics, used responsibly and with proper caution, would be for psychiatry what the microscope is for biology or the telescope is for astronomy.”
— Stanislav Grof, MD
At the forefront of mental healthcare innovation
We are dedicated to advancing psychedelic research and catalyzing personal wellness.
Read about usOur missionTo facilitate safe, legal access to psychedelics.
Our visionA new standard of mental healthcare informed by evidenced-based psychedelic treatments.
Press releases
View allNovamind Appoints Dr. Reid Robison as Chief Medical Officer
August 28, 2020
Novamind Sponsors TheraPsil, an Advocate for the Compassionate Use of Psilocybin in Canada
July 31, 2020
Novamind Closes the Acquisition of Cedar Psychiatry, a Leading Psychedelic Therapy Organization in the U.S.
July 30, 2020
Novamind Announces Closing of Oversubscribed Private Placement
July 14, 2020